Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.
The trial will take place in Melbourne and be conducted by Doherty Clinical Trials, a specialist not-for-profit organisation established by the Peter Doherty Institute for Infection and Immunity.
Doherty Clinical Trials CEO Dr Andrew Brockway said, “We are passionate about the development of new medicines for diseases with unmet medical needs and are excited to support Noxopharm through our extensive know-how and network of collaborators.”
HERACLES is the first-in-human trial of Noxopharm's novel drug candidate for autoimmune diseases, SOF-SKN. The trial will study the Australian company's candidate for the skin disease that is caused by cutaneous lupus erythematosus (CLE).
Noxopharm CEO Dr Gisela Mautner said: “We are very pleased to have secured such an outstanding organisation to host the HERACLES trial. The Doherty Clinical Trials team are experts in what they do, and we are looking forward to working closely with them as we take our innovative SOF-SKN drug for lupus into the clinic for the first time.”